Predicting sacral insufficiency fractures in carbon ion therapy for sacral chordoma: The role of RBE-weighted dose, dose-averaged LET, and volume
- PMID: 40804777
- DOI: 10.1002/mp.18045
Predicting sacral insufficiency fractures in carbon ion therapy for sacral chordoma: The role of RBE-weighted dose, dose-averaged LET, and volume
Abstract
Background: A previous retrospective analysis on clinical outcomes of carbon-ion radiation therapy (CIRT) for large sacral chordoma patients highlighted the potential correlation between tumor relapse and suboptimal dose-averaged LET (LETd) distribution, triggering the need for implementation of LETd-based objectives in clinical practice.
Purpose: To investigate the synergetic role played by RBE-weighted dose (DRBE) and LETd in the occurrence of sacral insufficiency fractures (SIF) after CIRT for sacral chordoma patients, in view of the clinical application of LETd-based plan optimization.
Methods: We retrospectively analyzed 73 patients, consecutively treated between 2013 and 2021, with radical CIRT and classified the occurrence of SIF during follow-up. The prescribed dose ranged from 70.4 to 76.8 Gy (RBE), in 16 fractions, according to the local-effect-model I (LEM). The median follow-up was 36 months (range 2-115). For all patients, sacral bone was contoured to calculate the corresponding DRBE- LETd- volume histogram (DLVH) with two RBE models. Logistic regression was used to investigate the relationship between median DLVH points of sacral bone and the likelihood of developing SIF. For patients reporting SIF at follow-up, the fracture was contoured on the corresponding MRI sequence for a loco-regional analysis.
Results: SIF was diagnosed in 50% of the patients, occurring after a median follow-up of 23 months (range 2-115). The volume of sacral bone receiving a DLEM higher than 69.8 Gy(RBE) and an LETd higher than 39.7 keV/µm was significantly higher in the fractured cohort (19.5 vs. 3.6 cc) and influenced the probability of toxicity over time (AUC 0.76). The majority of the fractures (63%) were located in the high-risk target volume.
Conclusion: Exposure of sacral bone to high-dose radiation with LETd values of the order of 40 keV/µm emerged as a significant predictor of SIF development. Further validation on larger patient cohorts is warranted to refine individual risk stratification and to inform safer LETd-based treatment planning.
Keywords: LETd optimization; carbon ion therapy; sacral chordoma.
© 2025 American Association of Physicists in Medicine.
Similar articles
-
Dose averaged linear energy transfer optimization for large sacral chordomas in carbon ion therapy.Med Phys. 2024 Jun;51(6):3950-3960. doi: 10.1002/mp.17102. Epub 2024 May 2. Med Phys. 2024. PMID: 38696546
-
How LEM-based RBE and dose-averaged LET affected clinical outcomes of sacral chordoma patients treated with carbon ion radiotherapy.Radiother Oncol. 2021 Oct;163:209-214. doi: 10.1016/j.radonc.2021.08.024. Epub 2021 Sep 17. Radiother Oncol. 2021. PMID: 34506829
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
-
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3. Syst Rev. 2024. PMID: 39593159 Free PMC article.
References
REFERENCES
-
- Bassler N, Toftegaard J, Lühr A, et al. LET‐painting increases tumour control probability in hypoxic tumours. Acta Oncol. 2014;53(1):25‐32. doi:10.3109/0284186X.2013.832835
-
- Imai R, Kamada T, Araki N, et al. Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. Int J Radiat Oncol Biol Phys. 2016;95(1):322‐327. doi:10.1016/j.ijrobp.2016.02.012
-
- Demizu Y, Imai R, Kiyohara H, et al. Carbon ion radiotherapy for sacral chordoma: a retrospective nationwide multicentre study in Japan. Radiother Oncol. 2021;154:1‐5. doi:10.1016/j.radonc.2020.09.018
-
- Tinganelli W, Durante M. Carbon ion radiobiology. Cancers. 2020;12:3022. doi:10.3390/cancers12103022
-
- Banfield W, Ioakeim‐Ioannidou M, Goldberg S, et al. Definitive high‐dose, proton‐based radiation for unresected mobile spine and sacral chordomas. Radiother Oncol. 2022;171:139‐145. doi:10.1016/j.radonc.2022.04.007
MeSH terms
LinkOut - more resources
Full Text Sources